SDGR earnings / call / takeaways
SDGR earnings call: key takeaways
What SDGR said on its earnings call of November 4, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.
By Lician·November 4, 2026·AI-generated from the call transcript and Lician data
- The company raised full-year 2026 guidance for ACV and drug discovery revenue. (10:26)
Results vs expectations
| Metric | Consensus | Reported | Result |
|---|---|---|---|
| EPS | -$0.65 | – | – |
| Revenue | $47.6M | – | – |
What changed since last quarter
- The company raised full-year ACV guidance to $222 to $232 million, up from previous expectations (10:26)
- Drug discovery revenue guidance was raised to $75 to $85 million, up from $65 to $75 million (10:26)
- The CEO emphasized the strong performance and confidence in the trajectory of the business. (16:00)
Guidance
What analysts pressed on
- - How much of the future growth will come from material science versus drug development " "- Concerns about the long-term viability of the predictive toxicology solution compared to traditional methods " "- Questions about the revenue contribution from Bunsen and customer willingness to pay for additional tokens (24:07)
In their words
Read the full transcript with the AI summary, or listen on the company's official webcast.
Every past call in full and transcript search come with Lician Pro.
Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.